Medpace Holdings, Inc. is a pharmaceutical company based in the United States of America with a low-risk ESG score of 17.2. It is a late-stage contract research organization that offers full-service drug development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device companies. In addition to this, Medpace provides bioanalytical laboratory services and imaging capabilities. Founded over 30 years ago, the company has over 5,400 employees in 40 countries. Headquartered in Cincinnati, Medpace operates globally in regions including Europe, Asia, South America, Africa, and Australia. Acquired by Cinven, a global private equity firm, in 2014 for $915 million, Medpace had a successful exit in 2018.